These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11344839)

  • 21. [Methods for increasing the efficacy and safety of Helicobacter pylori eradication regimens].
    Zakharova NV
    Eksp Klin Gastroenterol; 2006; (4):59-66. PubMed ID: 17269426
    [No Abstract]   [Full Text] [Related]  

  • 22. Is validation of Helicobacter pylori eradication necessary?
    Niv Y
    Isr Med Assoc J; 2003 Mar; 5(3):198-200. PubMed ID: 12725143
    [No Abstract]   [Full Text] [Related]  

  • 23. Helicobacter pylori and non-malignant diseases.
    Rokkas T; Simsek I; Ladas S
    Helicobacter; 2007 Oct; 12 Suppl 1():20-2. PubMed ID: 17727456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication.
    Wheeldon TU; Granström M; Hoang TT; Phuncarg DC; Nilsson LE; Sörberg M
    Aliment Pharmacol Ther; 2004 Jun; 19(12):1315-21. PubMed ID: 15191514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors for Helicobacter pylori resistance.
    Wallace MR
    Curr Gastroenterol Rep; 2002 Aug; 4(4):277. PubMed ID: 12149170
    [No Abstract]   [Full Text] [Related]  

  • 26. Therapy of Helicobacter pylori.
    McLoughlin R; Racz I; Buckley M; O'Connor HJ; O'Morain C
    Helicobacter; 2004; 9 Suppl 1():42-8. PubMed ID: 15347305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates.
    Romano M; Iovene MR; Russo MI; Rocco A; Salerno R; Cozzolino D; Pilloni AP; Tufano MA; Vaira D; Nardone G
    J Clin Pathol; 2008 Oct; 61(10):1112-5. PubMed ID: 18755715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary resistance of Helicobacter pylori to antimicrobial agents in Polish children.
    Rozynek E; Dzierzanowska-Fangrat K; Celińska-Cedro D; Jóźwiak P; Madaliński K; Dzierzanowska D
    Acta Microbiol Pol; 2002; 51(3):255-63. PubMed ID: 12588100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Helicobacter pylori: why are eradication results so variable?
    Katelaris PH
    J Gastroenterol Hepatol; 2004 Jun; 19(6):606-9. PubMed ID: 15151612
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of Helicobacter pylori.
    Wolle K; Malfertheiner P
    Best Pract Res Clin Gastroenterol; 2007; 21(2):315-24. PubMed ID: 17382279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New S3 guideline of DGVS for eradication of Helicobacter pylori--recommendations for routine general practice. Focus on the stomach bacterium].
    MMW Fortschr Med; 2009 May; 151(22):48-9. PubMed ID: 19526970
    [No Abstract]   [Full Text] [Related]  

  • 32. [Real-time PCR assay for rapid detection of clarithromycin-resistant helicobacter pylori in gastric biopsy specimens].
    Regnath T; Enninger A; Schalasta G
    Z Gastroenterol; 2004 Dec; 42(12):1371-5. PubMed ID: 15592960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance of Helicobacter pylori to antibiotics and its impact on treatment options.
    Mégraud F
    Drug Resist Updat; 2001 Jun; 4(3):178-86. PubMed ID: 11768331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Resistance to antibiotics used in Helicobacter pylori infection in children].
    Maciorkowska E; Kaczmarski M; Kowalczuk J; Kondej-Muszyńska K; Roszko I; Cieśla J; Zielińska A; Musaibili S
    Pol Merkur Lekarski; 2004 Jun; 16(96):543-6. PubMed ID: 15510893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Helicobacter pylori: microbiology and interactions with gastrointestinal microflora.
    Dzierzanowska-Fangrat K; Dzierzanowska D
    J Physiol Pharmacol; 2006 Sep; 57 Suppl 3():5-14. PubMed ID: 17033102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Sequential therapy regimen for Helicobacter pylori infection in children].
    Kalach N; Serhal L; Bergeret M; Spyckerelle C; Dupont C; Raymond J
    Arch Pediatr; 2008 Feb; 15(2):200-1. PubMed ID: 18249101
    [No Abstract]   [Full Text] [Related]  

  • 37. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin.
    Toracchio S; Capodicasa S; Soraja DB; Cellini L; Marzio L
    Dig Liver Dis; 2005 Jan; 37(1):33-8. PubMed ID: 15702857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary and secondary treatment for Helicobacter pylori in the United States.
    Vakil N
    Rev Gastroenterol Disord; 2005; 5(2):67-72. PubMed ID: 15976737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antimicrobial resistance and Helicobacter pylori: impacts on current and future therapies.
    Lee A; Hazell S
    Aust N Z J Med; 1998 Feb; 28(1):3-4, 17. PubMed ID: 9544378
    [No Abstract]   [Full Text] [Related]  

  • 40. Fosfomycin-containing second-line treatment for Helicobacter pylori infection.
    Barahona-Garrido J; Quiñonez NF; Cerda-Contreras E; Maria Sarti H; Téllez-Ávila FI
    Am J Gastroenterol; 2013 May; 108(5):858-9. PubMed ID: 23644971
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.